$637 Million is the total value of Samsara BioCapital, LLC's 48 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 16.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GRPH | GRAPHITE BIO INC | $121,804,000 | -46.7% | 7,431,623 | 0.0% | 19.11% | -32.2% | |
| NKTX | NKARTA INC | $56,585,000 | -12.2% | 2,034,703 | 0.0% | 8.88% | +11.5% | |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $43,089,000 | -3.7% | 3,376,888 | +6.6% | 6.76% | +22.4% |
| TIL | INSTIL BIO INC | $38,349,000 | -7.5% | 2,145,395 | 0.0% | 6.02% | +17.6% | |
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $36,305,000 | -6.8% | 1,565,526 | -0.0% | 5.70% | +18.4% |
| STRO | SUTRO BIOPHARMA INC | $31,652,000 | +1.6% | 1,675,579 | 0.0% | 4.97% | +29.2% | |
| CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $25,677,000 | -24.8% | 1,537,533 | 0.0% | 4.03% | -4.4% | |
| ISEE | Sell | IVERIC BIO INC | $23,756,000 | +77.1% | 1,462,834 | -31.2% | 3.73% | +125.1% |
| RAIN | Sell | RAIN THERAPEUTICS INC | $23,508,000 | -7.6% | 1,571,379 | -4.0% | 3.69% | +17.4% |
| ALLK | Buy | ALLAKOS INC | $18,219,000 | +45.9% | 172,089 | +17.7% | 2.86% | +85.5% |
| ALLK | Buy | ALLAKOS INCcall | $17,807,000 | +151.3% | 168,200 | +102.7% | 2.79% | +219.3% |
| RXRX | Sell | RECURSION PHARMACEUTICALS INcl a | $17,325,000 | -38.8% | 752,939 | -2.9% | 2.72% | -22.2% |
| NVAX | Sell | NOVAVAX INCcall | $17,124,000 | -59.4% | 82,600 | -58.4% | 2.69% | -48.4% |
| ACRS | ACLARIS THERAPEUTICS INC | $14,295,000 | +2.5% | 794,171 | 0.0% | 2.24% | +30.3% | |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $10,775,000 | -23.0% | 169,852 | 0.0% | 1.69% | -2.1% | |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $9,514,000 | -25.6% | 640,688 | 0.0% | 1.49% | -5.4% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $9,329,000 | -18.2% | 737,459 | 0.0% | 1.46% | +4.1% | |
| New | TANGO THERAPEUTICS INC | $9,051,000 | – | 700,000 | +100.0% | 1.42% | – | |
| JANX | Sell | JANUX THERAPEUTICS INC | $8,909,000 | -41.3% | 411,871 | -32.3% | 1.40% | -25.3% |
| SYRS | SYROS PHARMACEUTICALS INC | $8,624,000 | -18.6% | 2,189,199 | 0.0% | 1.35% | +3.4% | |
| ELEV | Buy | ELEVATION ONCOLOGY INC | $7,262,000 | -42.6% | 932,240 | +0.0% | 1.14% | -27.1% |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $7,026,000 | +14.2% | 883,720 | 0.0% | 1.10% | +45.2% | |
| DBTX | DECIBEL THERAPEUTICS INC | $6,372,000 | -10.3% | 826,422 | 0.0% | 1.00% | +14.0% | |
| NVAX | NOVAVAX INC | $6,252,000 | -2.4% | 30,160 | 0.0% | 0.98% | +24.2% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $6,089,000 | -16.2% | 1,111,112 | 0.0% | 0.96% | +6.5% | |
| VIRX | VIRACTA THERAPEUTICS INC | $5,703,000 | -29.3% | 711,039 | 0.0% | 0.90% | -10.1% | |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $5,383,000 | +45.6% | 549,250 | 0.0% | 0.84% | +85.3% | |
| EQ | EQUILLIUM INC | $5,034,000 | +15.8% | 738,176 | 0.0% | 0.79% | +47.1% | |
| JYAC | JIYA ACQUISITION CORP | $4,944,000 | -1.9% | 507,041 | 0.0% | 0.78% | +24.8% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $4,805,000 | +4.2% | 202,500 | 0.0% | 0.75% | +32.5% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $4,689,000 | +15.9% | 450,000 | 0.0% | 0.74% | +47.5% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $3,922,000 | -33.3% | 300,293 | 0.0% | 0.62% | -15.3% | |
| ALBO | ALBIREO PHARMA INC | $3,120,000 | -11.3% | 100,000 | 0.0% | 0.49% | +12.9% | |
| TERN | TERNS PHARMACEUTICALS INC | $3,012,000 | -15.0% | 289,068 | 0.0% | 0.47% | +8.2% | |
| BLSA | BCLS ACQUISITION CORP | $2,988,000 | -5.4% | 300,000 | 0.0% | 0.47% | +20.3% | |
| BCEL | ATRECA INC | $2,472,000 | -26.9% | 396,835 | 0.0% | 0.39% | -7.0% | |
| IMCR | IMMUNOCORE HLDGS PLCads | $2,372,000 | -5.1% | 64,000 | 0.0% | 0.37% | +20.8% | |
| New | SURROZEN INC | $2,124,000 | – | 300,000 | +100.0% | 0.33% | – | |
| ALVR | ALLOVIR INC | $2,063,000 | +27.0% | 82,336 | 0.0% | 0.32% | +61.2% | |
| ODT | ODONATE THERAPEUTICS INC | $2,038,000 | -16.6% | 700,421 | 0.0% | 0.32% | +6.0% | |
| KRON | KRONOS BIO INC | $1,638,000 | -12.5% | 78,131 | 0.0% | 0.26% | +11.3% | |
| BNTX | BIONTECH SEsponsored ads | $1,572,000 | +22.0% | 5,758 | 0.0% | 0.25% | +55.3% | |
| KALA | KALA PHARMACEUTICALS INC | $1,575,000 | -50.6% | 601,162 | 0.0% | 0.25% | -37.2% | |
| VTGN | Sell | VISTAGEN THERAPEUTICS INC | $1,339,000 | -42.0% | 488,632 | -33.3% | 0.21% | -26.3% |
| RCKT | ROCKET PHARMACEUTICALS INC | $1,212,000 | -32.5% | 40,550 | 0.0% | 0.19% | -14.4% | |
| NGM | Sell | NGM BIOPHARMACEUTICALS INC | $287,000 | -20.1% | 13,669 | -25.0% | 0.04% | +2.3% |
| New | ASTRIA THERAPEUTICS INC | $221,000 | – | 25,000 | +100.0% | 0.04% | – | |
| AMRN | AMARIN CORP PLCspons adr new | $128,000 | +16.4% | 25,000 | 0.0% | 0.02% | +42.9% | |
| Exit | Catabasis Pharmaceuticals Inc | $0 | – | -150,000 | -100.0% | -0.04% | – | |
| LSAQ | Exit | Lifesci Acquisition II Corp | $0 | – | -200,000 | -100.0% | -0.25% | – |
| ALPN | Exit | Alpine Immune Sciences Inc | $0 | – | -275,169 | -100.0% | -0.31% | – |
| CHFWU | Exit | Consonance HFW Acquisition Co | $0 | – | -300,000 | -100.0% | -0.38% | – |
| BCTG | Exit | BCTG Acquisition Corp | $0 | – | -500,000 | -100.0% | -0.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.